CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

By DiJoseph John   Dougher Maureen   Armellino Douglas   Kalyandrug Lyka   Kunz Arthur   Boghaert Erwin   Hamann Philip   Damle Nitin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 7, 2007-07 ,pp. : 1107-1117

Springer Publishing Company

Access to resources Recommend Favorite

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma

By Schütt P.   Zimmermann K.   Derks C.   Ebeling P.   Welt A.   Poser M.   Hense J.   Metz K.   Anhuf J.   Sandmann M.   Neise M.   Moritz T.   Stuschke M.   Niederle N.   Seeber S.   Nowrousian Mohammad  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 459-466

Springer Publishing Company

Access to resources Recommend Favorite

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye   Polson Andrew  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma: single institution experience

By Wang Bufei   Huang Huiqiang   Bu Qing   Xia Zhongjun   Lin Xubin   Wang Fenghua   Li Yuhong   Peng Yulong   Pan Zhanhe   Wang Shusen   Lin Tongyu   Jiang Wenqi   Guan Zhongzhen  

The Chinese-German Journal of Clinical Oncology, Vol. 5, Iss. 6, 2006-12 ,pp. : 402-406

Springer Publishing Company

Access to resources Recommend Favorite

Pralatrexate: treatment of T-cell non-Hodgkin’s lymphoma

By Parker Terri   Barbarotta Lisa   Foss Francine  

Future Oncology, Vol. 9, Iss. 1, 2013-01 ,pp. : 21-29

Future Medicine

Access to resources Recommend Favorite